Why is it so often said that almost nothing is known about ME/CFS?

I've started typing my answer a few times, now...

And we're glad you did - excellent summary.

2-day CPET (with 48 hours inbetween) seems to be the best biomarker for now - but they've always been small studies and have seemingly struggled to get traction. Does anybody know if there's anybody trying to replicate on larger numbers and (just as important) trying on other diseases to demonstrate drop off on the second day is unique to ME/CFS?
 
I may be interpreting it wrong but it is listed as "and/or"
The quote from the CCC has the heading:

Post-exertional malaise and/or Fatigue:

I think this has, unfortunately, been poorly written. It could be interpreted as

(Post-exertional malaise) and/or (Fatigue):

which is how you have interpreted it, or as

Post-exertional (malaise and/or Fatigue):

which is how I think the rest of the following text implies it should be interpreted and how I think @JaimeS is interpreting.
 
What an excellent summary. Are there even 100 papers that are high quality and replicated in a larger number?

I don't believe so, but I am a research novice.

IMO, NKC comes closest to validation, with over a dozen (small!) studies showing low function in pwME. If someone were to write a meta-analysis paper, they might be able to say something by now. But you'd have to take it through that meta-analysis process, in which studies are eliminated as not being applicable (for various possible reasons). You may find you have to eliminate a lot of them.

Everything else is:

1) Unreplicated, or only replicated once or twice
2) Replicated using the exact same patient cohort, which is problematic
and/or
3) Too small
 
I don't believe so, but I am a research novice.

IMO, NKC comes closest to validation, with over a dozen (small!) studies showing low function in pwME. If someone were to write a meta-analysis paper, they might be able to say something by now. But you'd have to take it through that meta-analysis process, in which studies are eliminated as not being applicable (for various possible reasons). You may find you have to eliminate a lot of them.

Even then, it's hard to argue that NKC function would be a valid biomarker for ME/CFS given reduced NK cell function is also seen in depression:
(Now, that might be to be expected given the increasing suspicion that certain types of depressive disorder may themselves be neuroimmune in nature - however, it suggests to me that NK cell dysfunction doesn't provide a biomarker that would distinguish an ME/CFS patient from a patient with MDD. And given the selection problems with ME/CFS studies it also leads us to have to ensure that the studies that found reduced NK function did sufficient screening to exclude MDD patients)
 
I don't believe so, but I am a research novice.

IMO, NKC comes closest to validation, with over a dozen (small!) studies showing low function in pwME. If someone were to write a meta-analysis paper, they might be able to say something by now. But you'd have to take it through that meta-analysis process, in which studies are eliminated as not being applicable (for various possible reasons). You may find you have to eliminate a lot of them.

Everything else is:

1) Unreplicated, or only replicated once or twice
2) Replicated using the exact same patient cohort, which is problematic
and/or
3) Too small
Maybe we should start a list of studies with 50+ subjects? No Oxford, no psychology, no subjective questionnaires.
 
Thinking about this sentence. Is it the last major disease we know almost nothing about? genuine question. I've heard or read Ron Davis say this, and I understand where he's coming from, but I don't know that it is.


That wikipedia link doesn't include the disease Acute Flaccid Myelitis. Which to my mind resembles some cases of Severe ME in children? It appears that there may be an enterovirus connection, though it's only been found in a few cases.

ACUTE FLACCID MYELITIS - NORTH AMERICA (10): USA (NEBRASKA)
************************************************************
A ProMED-mail post
<http://www.promedmail.org>
ProMED-mail is a program of the
International Society for Infectious Diseases
<http://www.isid.org>

In this posting:
[1] Nebraska: 1st AFM case
[2] CDC update

******
[1] Nebraska: 1st AFM case
Date: Wed 28 Nov 2018
Source: Nebraska TV/KHGI [edited]
<https://nebraska.tv/news/local/first-confirmed-case-of-acute-flaccid-myelitis-reported-to-dhhs>


A child in the Sarpy/Cass Health Department area had the 1st confirmed
case of acute flaccid myelitis (AFM) in Nebraska. AFM is a condition
that causes muscle weakness. The child was hospitalized and later
released. The case was reported to the Nebraska Department of Health
and Human Services (DHHS).

One additional suspected case, also in the Sarpy/Cass Health
Department jurisdiction, is undergoing further testing at the Centers
for Disease Control and Prevention (CDC). Another reported case in
Douglas county was not confirmed after a thorough review by the CDC.
The patient met some, but not all of the criteria for being a
confirmed AFM case.

"AFM is a rare but serious condition that affects mostly children, and
we've been watching closely for cases in Nebraska over the last 4
years," said State Epidemiologist for DHHS Dr. Tom Safranek. "There is
still a lot to learn about AFM and more study is needed. State and
local health departments nationwide are working with federal partners
to investigate cases and the possible causes."

AFM is not a new condition, but there has been an increase in cases
nationwide since 2014. From August 2014 through October 2018, there
have been a total of 440 confirmed cases of AFM in the US.

DHHS started surveillance for AFM in 2014 after cases appeared in
Colorado and made it a reportable disease in 2016. The department has
shared information on recognizing, managing and reporting potential
cases of AFM with health care providers and local health departments
across the state.

DHHS also listed these facts about AFM:
- AFM is a condition that generally causes sudden muscle weakness.
Symptoms include sudden weakness in the arms or legs. Some people also
experience drooping of the eyelids or face, difficulty moving eyes,
slurred speech, or difficulty swallowing.
- If parents see potential symptoms of AFM in their child, they should
contact their health care provider promptly.
- Experts are working to determine the exact cause of AFM. There is no
specific treatment for AFM or proven prevention strategy, but washing
hands, covering your cough and staying home if you're sick can help
avoid illness.

--
Communicated by:
ProMED-mail from HealthMap Alerts
<promed@promedmail.org>

[HealthMap/ProMED-mail map of Nebraska, United States:
<http://healthmap.org/promed/p/229>
Nebraska county map:
<https://www.mapsofworld.com/usa/states/nebraska/maps/nebraska-county-map.jpg>

*****
[2] CDC update
Date: Tue 27 Nov 2018
Source: Daily Mail online [edited]
<https://www.dailymail.co.uk/health/...ing-polio-like-disease-spreads-31-states.html>


The mysterious, rare 'polio-like' disease blighting the US has now
spread to 31 states, sickening at least 116 children. And yet,
officials still have no idea what causes acute flaccid myelitis (AFM),
nor how to treat or prevent it.

The poorly understood illness, which can cause paralysis and, in rare
cases, prove deadly, has struck Colorado the hardest, followed by
Texas.

The Centers for Disease Control and Prevention (CDC) is currently
investigating a further 170 cases of people with tell-tale symptoms of
AFM.

There has already been more than 3.5 times as many cases as last year
[2017], but doctors remain baffled as to what is causing the illness.

The CDC put out its most recent figures on [Tue 27 Nov 2018], showing
there have been 286 reports of people suffering from acute flaccid
myelitis (AFM) in 31 states, with 116 of those cases confirmed.

More than 90 percent of people affected by the illness are under 18
and the average age of patients is 4.

It is believed to be caused by a combination of viruses and children
usually first show signs of a fever and a cough for three to 10 days.

--
Communicated by:
ProMED-mail from HealthMap Alerts
<promed@promedmail.org>

[CDC is concerned about AFM, a serious illness that we do not know the
cause of or how to prevent it.
- CDC is investigating the increase in AFM in 2018. As of November
2018, 31 states have reported confirmed AFM cases.
- Even with an increase in cases in 2014, 2016, and now in 2018, AFM
remains a very rare disease (less than one in a million).
- CDC is intensifying efforts to understand the cause and risk factors
of AFM.

It is always important to practice disease prevention steps, like
washing your hands, staying up-to-date on vaccines, and protecting
yourself from mosquito bites. - Mod.UBA]

[See Also:
Acute flaccid myelitis - North America (09): USA
http://promedmail.org/post/20181116.6145865
Acute flaccid myelitis - North America (08): USA
http://promedmail.org/post/20181110.6131199
Acute flaccid myelitis - North America (07): USA (WI)
http://promedmail.org/post/20181102.6123836
Acute flaccid myelitis - North America (06): USA, increase in cases
http://promedmail.org/post/20181024.6106438
Acute flaccid myelitis - North America (05): USA, increase in cases
http://promedmail.org/post/20181018.6097500
Acute flaccid myelitis - North America (04): human enterovirus D68
(NY) EV-D68 http://promedmail.org/post/20181014.6090709
Acute flaccid myelitis - North America (03): USA, increase in susp
cases http://promedmail.org/post/20181013.6085691
Acute flaccid myelitis - North America (02): (USA)
http://promedmail.org/post/20181010.6081500
Acute flaccid myelitis - North America: USA (CO)
http://promedmail.org/post/20180315.5687686
2017
---
Acute flaccid myelitis: human enterovirus D68
http://promedmail.org/post/20171103.5423175
Acute flaccid myelitis - Europe: Germany
http://promedmail.org/post/20170912.5311829
2016
---
Acute flaccid myelitis - North America (09): USA
http://promedmail.org/post/20161215.4702290
Acute flaccid myelitis - North America (08): USA (AZ,WA) RFI
http://promedmail.org/post/20161117.4637077
Acute flaccid myelitis - North America (07): USA (WA), responses to
RFI http://promedmail.org/post/20161103.4605193
Acute flaccid myelitis - North America (06): USA causes, RFI
http://promedmail.org/post/20161101.4598660
Acute flaccid myelitis - North America (05): USA
http://promedmail.org/post/20161030.4596196
Acute flaccid myelitis - North America (04): USA
http://promedmail.org/post/20161030.4596196
Acute flaccid myelitis - North America (03): USA
http://promedmail.org/post/20161008.4545994
Acute flaccid myelitis - North America (02): USA, Canada, human
enterovirus D68 http://promedmail.org/post/20161002.4530332
Acute flaccid myelitis - North America: USA, human enterovirus D68
susp. http://promedmail.org/post/20160923.4509548
Human enterovirus D68 - Netherlands: acute flaccid myelitis
http://promedmail.org/post/20160925.4513491
Acute flaccid myelitis - USA: human enterovirus D68 susp.
http://promedmail.org/post/20160923.4509548
Human enterovirus D68 - Taiwan, Canada: acute flaccid paralysis
http://promedmail.org/post/20160902.4461647
Human enterovirus D68 - USA (CO) acute flaccid paralysis
http://promedmail.org/post/20160728.4375980]
.................................................sb/uba/mj/ml

------------------------------
 
I may be interpreting it wrong but it is listed as "and/or"
The quote from the CCC has the heading:

Post-exertional malaise and/or Fatigue:

I think this has, unfortunately, been poorly written. It could be interpreted as

(Post-exertional malaise) and/or (Fatigue):

which is how you have interpreted it, or as

Post-exertional (malaise and/or Fatigue):

which is how I think the rest of the following text implies it should be interpreted and how I think @JaimeS is interpreting.
This is indeed the biggest and most contentious issue with the CCC. It's also the reason why the London Revised criteria were created, and why many of the specialists who wrote the CCC went on to write the ICC.

It's generally considered that the criteria requires post-exertional malaise or post-exertional fatigue, and that this is separate from the general fatigue criteria. I think they were probably trying to capture the idea of rapid fatiguability after exertion (think the latest hand-grip hand strength test) as well as the delayed and prolonged decline in aerobic metabolism (as per the CPET).

The problem is that this could too easily be interpreted as simply an increase in fatigue after exertion. Which may be present in most patients, but doesn't take into account the full breadth of symptom worsening.
2-day CPET seems to produce a pretty standard pattern... in some pwME. There's a second group who, according to one clinician who's worked on this for decades, look more like very elderly people on day one & replicate that on day 2. I had a one-day CPET where the ANS specialist said I functioned "like an 80-year-old" so this checks out. So even PEM has its variance.
I think that it's possible these patients may be experiencing PEM on day one, so they repeat their results. I'd be interested to see if these patients experience the rapid weakness that the HGS test attempts to show instead, or if they don't have that, either.
 
The quote from the CCC has the heading:

Post-exertional malaise and/or Fatigue:

I think this has, unfortunately, been poorly written. It could be interpreted as

(Post-exertional malaise) and/or (Fatigue):

which is how you have interpreted it, or as

Post-exertional (malaise and/or Fatigue):

which is how I think the rest of the following text implies it should be interpreted and how I think @JaimeS is interpreting.

I think you must be right 'Post-exertional (malaise and/or Fatigue)' given the context seems most likely what was intended.

So 'post-exertional malaise and/or fatigue and/or pain' should be interpreted as 'post-exertional (malaise and/or fatigue and/or pain)'.

Effectively saying at least one from from the following list
  • post-exertional malaise
  • post-exertional fatigue
  • post-exertional pain
 
Thinking about this, in detail, for probably the first time, the is a difficulty about the concepts of post-exertional fatigue and pain. What counts as "post" and what counts as "exertion"? It should surely be "abnormal or unexpected post-exertional fatigue or pain".

If you are running a marathon, not that I have, by the time you get to twelve miles you are probably feeling a degree of fatigue and pain. You have already run some distance so it is post that exertion, but is still prior to the remaining exertion. These are difficult ideas. It is different to the malaise which there is no reasonable reason to expect to be related to exertion.
 

Researchers & clinicians need to listen carefully to pwME
in order to be successful.

If you're in science and you're reading this, there is so much you don't know that a pwME can tell you. The fact that you're here and listening speaks well for you. Get a pwME with a science background to help you design your study. It will go SO MUCH BETTER. You will avoid SO MANY MISTAKES.

Don't do it for brownie points. Don't do it because your grant says "you gotta".

Do it because you'll produce a crappier study without us.

x gazillion.
 
I think you must be right 'Post-exertional (malaise and/or Fatigue)' given the context seems most likely what was intended.

So 'post-exertional malaise and/or fatigue and/or pain' should be interpreted as 'post-exertional (malaise and/or fatigue and/or pain)'.

Effectively saying at least one from from the following list
  • post-exertional malaise
  • post-exertional fatigue
  • post-exertional pain
That’s slight fudging is why some people don’t like ccc criteria and the fudging is worse in Nice Criteria which don’t mention pain as post exertion effect. I think how my ME presents post exertion is nothing like excess fatigue and I dislike the conflation. I think it’s much better expressed as global exacerbation of symptoms with it understood that there is a lot of distressing symptoms associated with the illness. Having as NICE do, fatigue, PEF and at minimum one additional symptom eg insomnia or headaches, I think is inaccurate characterisation or capturing of what I regard as classic ME. We had long discussion on PEM when Jason was doing his new questionnaire on it.
 
Last edited:
How much we know about ME could be plotted on a range, spectrum, or continuum, depending on your science/medical background, and who your audience is.

From a pwME point of view who is a bit sciency, but not tons, I maintain we know
enough to see ME is biomedical. Diagnosis of MS combines a few tests. Why not ME? Dr. Lily Chu lists tests that in combination certainly show abnormalities: the 2day CPET, tilt table, neuropsychological testing, brain imaging, and NK cell function/numbers.

As a pwME it is frustrating to repeatedly read we know very little about ME, or there are no tests that show abnormalities. We know some, and we can do some tests in
combination. However, despite these first important steps, we hear almost nothing is known. As I said earlier, it depends who your audience is; what's their perspective?Biomedical researchers know some, but are also aware there is MUCH more to learn. PwME know some progress has been made, but there is much more to learn. The uninformed, however, may interpret no testing available, unknown entity etc. as MUS; that there is nothing to learn. I think it depends who is speaking, and who is listening.
 
Thinking about this sentence. Is it the last major disease we know almost nothing about? genuine question. I've heard or read Ron Davis say this, and I understand where he's coming from, but I don't know that it is.

I was surprised that for example migraine is in the WHO's list of top ten most disabling conditions.
I agree. Another example would be EDS. Genes have been found for many types (seven?), but some of those genes have an unclear relationship to collagen.

There’s a very large group, the hypermobile group, most of whom still have no gene identified (although it has an autosomal dominant form of inheritance, so the genes are following Mendelian rules so it seems not that hard—yet hasn’t been found, but I don’t think there’s many researchers, much funding, or many studies here, either), and is thought to be likely to end up in several categories eventually.

Plus there’s the split-off diagnosis for people who don’t quite fit the new stricter criteria but have associated symptoms, so clearly don’t have just benign joint hypermobility.
 
Last edited:
Even then, it's hard to argue that NKC function would be a valid biomarker for ME/CFS given reduced NK cell function is also seen in depression:
Low NK cell function is seen in a lot of conditions.

It’s not a specific biomarker.

However, there’s precedent for using non-specific biomarkers in combination with clinical picture and differential diagnosis, in other diseases when specific biomararkers don’t yet exist, as part of a diagnostic process.

Think about autoimmune diseases, where they use elevated SED and increased ANA, even though these are found in many different diseases (including some of different categories, such as infection).

The problem I am hearing said in webinars from people who use this experimentally is they worry there aren’t enough labs that know how to do it, doctors don’t know how to order it (I think you have to use a vague code and then specify the test), and there’s a time constraint for getting the samples to the lab, because it can’t be frozen.

I don’t think any of those problems are things that can’t be solved.
 
Last edited:
Now, that might be to be expected given the increasing suspicion that certain types of depressive disorder may themselves be neuroimmune in nature - however, it suggests to me that NK cell dysfunction doesn't provide a biomarker that would distinguish an ME/CFS patient from a patient with MDD.

...or several other things. Including emotional trauma and physical trauma -- anything that would induce a flood of cortisol -- as in severe, severe stressor -- can knock out NKCs. Or so says some pretty preliminary research that looks credible at first glance.

Maybe we should start a list of studies with 50+ subjects? No Oxford, no psychology, no subjective questionnaires.

That's not a bad idea. We're basically saying a very rudimentary meta-analysis. Find out just how deep a hole we're in.

[Edit: I wonder if anyone who worked on the IOM report already has such a list? They did review 9K studies, after all.]
 
Last edited:
Back
Top Bottom